CDKN2A and non-small cell lung carcinoma: NSCLC patients with p16 promoter hypermethylation were significantly correlated with shorter DFS, and the combined HR was 1.68 (95% CI: 1.12–2.52) without significant heterogeneity (p = 0.134, as figure 2 shows).